Parkman Healthcare Partners LLC Buys Shares of 753,752 KalVista Pharmaceuticals, Inc. $KALV

Key Points

• Parkman Healthcare Partners LLC has acquired a new stake in KalVista Pharmaceuticals worth approximately $8.70 million, owning 1.52% of the company as of the most recent SEC filing.
• Wall Street analysts have upgraded their price targets for KalVista Pharmaceuticals, with projections reaching as high as $27.00 and a consensus rating of "Buy" across multiple analysts.
• KalVista Pharmaceuticals reported a significant earnings miss last quarter, with an EPS of ($3.69) compared to expectations of ($0.83).

Parkman Healthcare Partners LLC acquired a new position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 753,752 shares of the specialty pharmaceutical company's stock, valued at approximately $8,698,000. Parkman Healthcare Partners LLC owned 1.52% of KalVista Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Wells Fargo & Company MN boosted its position in shares of KalVista Pharmaceuticals by 29.1% in the 4th quarter. Wells Fargo & Company MN now owns 20,165 shares of the specialty pharmaceutical company's stock worth $171,000 after purchasing an additional 4,543 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in KalVista Pharmaceuticals by 14.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 696,037 shares of the specialty pharmaceutical company's stock valued at $5,895,000 after buying an additional 89,001 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after acquiring an additional 5,502 shares in the last quarter. Algert Global LLC purchased a new stake in shares of KalVista Pharmaceuticals in the fourth quarter worth $88,000. Finally, Ameriprise Financial Inc. purchased a new stake in shares of KalVista Pharmaceuticals in the fourth quarter worth $452,000.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 2,942 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.22, for a total value of $38,893.24. Following the transaction, the insider directly owned 119,841 shares in the company, valued at $1,584,298.02. This trade represents a 2.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Benjamin L. Palleiko sold 32,979 shares of the company's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total value of $517,440.51. Following the sale, the chief executive officer owned 369,595 shares of the company's stock, valued at approximately $5,798,945.55. This trade represents a 8.19% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 59,835 shares of company stock worth $892,350 over the last three months. Insiders own 4.30% of the company's stock.

Analyst Upgrades and Downgrades

KALV has been the topic of a number of analyst reports. HC Wainwright upped their price target on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Leerink Partners upped their target price on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a research note on Monday, July 7th. Finally, JMP Securities raised their price target on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a "market outperform" rating in a research report on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company's stock. Based on data from MarketBeat, KalVista Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $26.29.

KalVista Pharmaceuticals Stock Performance

Shares of KALV stock traded down $0.58 during trading hours on Thursday, reaching $14.81. The company had a trading volume of 2,891,099 shares, compared to its average volume of 805,068. The business has a fifty day moving average price of $14.04 and a 200-day moving average price of $12.74. KalVista Pharmaceuticals, Inc. has a one year low of $7.30 and a one year high of $17.28. The firm has a market cap of $745.54 million, a PE ratio of -4.01 and a beta of -0.10.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last issued its quarterly earnings data on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.21). The company had revenue of $1.43 million for the quarter, compared to the consensus estimate of $1.97 million. Equities research analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).